toripalimab

Overview

Toripalimab is an anti-PD-1 monoclonal antibody targeting PDCD1. It is recommended by NCCN guidelines (with penpulimab) as part of first-line combination regimens with platinum-based chemotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Toripalimab (anti-PD-1) + platinum/gemcitabine is NCCN-recommended first-line standard for R/M NPC alongside penpulimab; ICI recommended as salvage if not used initially PMID:24952746.
• Anti-LAG-3 LBL-007 + toripalimab in R/M NPC (NCT05102006, n=30): ORR 33.3% in ICI-naïve (n=12) and 11.8% in ICI-refractory (n=17); median PFS 10.8 months; median DOR 15 months PMID:24952746.
• A2AR antagonist ILB-2109 + toripalimab under investigation in phase Ib/IIa for R/M NPC PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.